The Simon Linder team at the Netherlands Research Institute carried out a comprehensive polynomial analysis of tissues isolated after 3 months of AR-targeted enzalutamide monotherapy in patients with high-risk prostate cancer (Linder et al., 2022). Here, AR is linked to prostate carcinoma.